BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35621644)

  • 1. Progressing Vulvar Melanoma Caused by Instability in cKIT Juxtamembrane Domain: A Case Report and Review of Literature.
    Englert-Golon M; Budny B; Lewandowska M; Burchardt B; Smolarek N; Ziemnicka K; Jagodziński PP; Ruchała M; Grabowska M; Sajdak S
    Curr Oncol; 2022 Apr; 29(5):3130-3137. PubMed ID: 35621644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
    Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
    Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
    Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
    Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
    Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
    [No Abstract]   [Full Text] [Related]  

  • 6. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report.
    Mordoh A; Triviño Pardo JC; Carri I; Barrio MM; Mordoh J; Aris M
    BMC Med Genomics; 2023 Jan; 16(1):1. PubMed ID: 36604730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets.
    Flaherty KT
    Clin Exp Metastasis; 2012 Oct; 29(7):841-6. PubMed ID: 22661223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected distribution of cKIT and BRAF mutations among southern Italian patients with sinonasal melanoma.
    Colombino M; Lissia A; Franco R; Botti G; Ascierto PA; Manca A; Sini MC; Pisano M; Paliogiannis P; Tanda F; Palmieri G; Cossu A
    Dermatology; 2013; 226(3):279-84. PubMed ID: 23817129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
    Siroy AE; Boland GM; Milton DR; Roszik J; Frankian S; Malke J; Haydu L; Prieto VG; Tetzlaff M; Ivan D; Wang WL; Torres-Cabala C; Curry J; Roy-Chowdhuri S; Broaddus R; Rashid A; Stewart J; Gershenwald JE; Amaria RN; Patel SP; Papadopoulos NE; Bedikian A; Hwu WJ; Hwu P; Diab A; Woodman SE; Aldape KD; Luthra R; Patel KP; Shaw KR; Mills GB; Mendelsohn J; Meric-Bernstam F; Kim KB; Routbort MJ; Lazar AJ; Davies MA
    J Invest Dermatol; 2015 Feb; 135(2):508-515. PubMed ID: 25148578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
    Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
    J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.
    Lokhandwala PM; Tseng LH; Rodriguez E; Zheng G; Pallavajjalla A; Gocke CD; Eshleman JR; Lin MT
    BMC Cancer; 2019 Jul; 19(1):665. PubMed ID: 31277584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
    Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
    Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant Melanoma of Vulva and Vagina: A Histomorphological Review and Mutation Analysis--A Single-Center Study.
    Rouzbahman M; Kamel-Reid S; Al Habeeb A; Butler M; Dodge J; Laframboise S; Murphy J; Rasty G; Ghazarian D
    J Low Genit Tract Dis; 2015 Oct; 19(4):350-3. PubMed ID: 26225944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
    Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
    JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutations might be more common than supposed in vulvar melanomas.
    Wylomanski S; Denis MG; Théoleyre S; Bouquin R; Vallée A; Knol AC; Saint-Jean M; Peuvrel L; Dréno B; Quéreux G
    Exp Dermatol; 2018 Feb; 27(2):210-213. PubMed ID: 29178146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.
    Kim J; Lazar AJ; Davies MA; Homsi J; Papadopoulos NE; Hwu WJ; Bedikian AY; Woodman SE; Patel SP; Hwu P; Kim KB
    J Cutan Pathol; 2012 Sep; 39(9):821-5. PubMed ID: 22809251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT Suppresses BRAF
    Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
    Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond the BRAF
    Richtig G; Hoeller C; Kashofer K; Aigelsreiter A; Heinemann A; Kwong LN; Pichler M; Richtig E
    Br J Dermatol; 2017 Oct; 177(4):936-944. PubMed ID: 28278349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.